Sec. 110. Opioid review modernization

423 words·~2 min read·/bill/114/hr/5189/ih/section-110·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 569 of such Act ( 21 U.S.C. 350bbb–8 ) the following: Subject to paragraph (2), prior to the approval pursuant to an application under section 505(b) of a new drug that is an opioid and does not have abuse-deterrent properties, the Secretary shall refer the application to an advisory committee of the Food and Drug Administration to seek recommendations from such advisory committee. A referral to an advisory committee under paragraph

(1)is not required with respect to a new drug if the Secretary— finds that such a referral is not in the interest of protecting and promoting public health; finds that such a referral is not necessary based on a review of the relevant scientific information; and submits a notice containing the rationale for such findings to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives. The Secretary shall convene the Pediatric Advisory Committee of the Food and Drug Administration to seek recommendations from such Committee regarding a framework for the inclusion of information in the labeling of drugs that are opioids relating to the use of such drugs in pediatric populations before the Secretary approves any labeling or change to labeling for any drug that is an opioid intended for use in a pediatric population. The requirements of subsections

(a)and

(b)shall cease to be effective on October 1, 2022. . Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, as part of the Food and Drug Administration’s evaluation of the Extended-Release/Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, and in consultation with relevant stakeholders, shall develop recommendations regarding education programs for prescribers of opioids pursuant to section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ), including recommendations on— which prescribers should participate in such programs; and how often participation in such programs is necessary. Not later than 2 years after the end of the period for public comment on the draft guidance entitled General Principals for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products issued by the Center for Drug Evaluation and Research of the Food and Drug Administration in March 2016, the Commissioner of Food and Drugs shall publish in the Federal Register a final version of such guidance.

Connections2 off-index

2 references not yet in our index

21 USC 350bbb–8
21 USC 355–1

Citation graph

cites case law

Sec. 110

Opioid review modernization

Cite21 USC 350bbb–8

Cite21 USC 355–1

Cites 2Cited by 0 across 0 sources